Company’s fifth peer-reviewed publication shows seniors engage with the Omada Program and lose weight; model estimates savings in less than two years
San Francisco, CA; (October 13, 2016) – As the Center for Medicare and Medicaid Services (CMS) works to finalize a diabetes prevention program for beneficiaries, Omada Health today announced the publication of a study demonstrating its program’s effectiveness with individuals 65 and older. Published in the peer-reviewed journal PLOS ONE, the published research contained data from more than 1,100 senior participants in the Omada program. Those participants started the Omada program, with an average age of 69 years old and BMI of 32.5 kg/m2.
Six months after beginning the Omada program, 89.5% of participants in the study completed at least nine of 16 lessons. Twenty-six weeks after beginning the Omada Program, average weight loss for program completers was 7.3%, while average weight loss for all participants was 6.8%. Estimated savings from the population included in the study were $1,770 over three years per participant, with additional savings accumulating over the next decade.
“This study validates what our team has known for a while: that American seniors can – and will – reduce their risk of chronic disease by engaging with a properly designed digital health intervention,” said Omada co-founder and CEO Sean Duffy. “The evidence from this study shows that the Omada program delivers clinically-meaningful health outcomes and significant savings for those 65 and older. This publication is a demonstration of our company’s values in action.”
Read More: https://www.omadahealth.com/news/peer-reviewed-study-demonstrates-omada-program-helps-seniors-reduce-risk-of-type-2-diabetes-and-heart-disease
Peer-Reviewed Study Demonstrates Omada Program Helps Seniors Reduce Risk of Type 2 Diabetes and Heart Disease
Via: Omada Health
OncoMed Presents Interim Phase 1b Data for Ipafricept and Vantictumab in Pancreatic Cancer at the ESMO 2016 Congress
COPENHAGEN, Denmark and REDWOOD CITY, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) today announced the presentation of interim clinical data from its ongoing Phase 1b trials of ipafricept (FZD8-Fc, OMP-54F28) and vantictumab (anti-Fzd, OMP-18R5) at the European Society of Medical Oncology (ESMO) 2016 Congress.
In-center self-care hemodialysisis associated with better outcomes than traditional in-center hemodialysis.
While Omada Health’s Prevent program is designed for individuals with prediabetes, it can be adapted to patients who already have diabetes, because the program is built on behavior change and modification, explained Mike Payne, MBA, MSci, chief healthcare development officer at Omada Health.
Silk Road Medical Announces New Medicare Coverage Option for TransCarotid Artery Revascularization (TCAR) Procedures
Via: PR Newswire
Medicare to Cover Procedures within the TCAR Surveillance Project Sponsored by the Society for Vascular Surgery
NEW CAROTID ARTERY STENT PROCEDURE TO BE EVALUATED BY
Edward R Jones, MD, MBA, FACP LaRhondd James, RN Sophid Rosen, PhD
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer
Results Expected in the First Half of 2017
NN&I interviewed Leslie Trigg, CEO of Outset Medical, on the company's new Tablo dialysis machine, which is aimed at clinics who want to develop the self-care option for patients.
By: Sarah S. Prichard, MD, FRCP(C) Glenn M. Chertow, MD, MPH